Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases

Mario Airoldi, Massimiliano GARZARO, Fulvia Pedani, Oliviero Ostellino, Giovanni Succo, Giuseppe Riva, Matteo Sensini, Nertila Naqe, Elisa Bellini, Luca Raimondo, Giancarlo Pecorari

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme.
Lingua originaleInglese
pagine (da-a)86-90
Numero di pagine5
RivistaAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume40
Numero di pubblicazione1
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Cisplatin
  • Female
  • Head and Neck Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prospective Studies
  • Salivary Gland Neoplasms
  • Treatment Outcome
  • Vinblastine
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases'. Insieme formano una fingerprint unica.

Cita questo